Clinical Trials Browser

Phase 1 × Gastrointestinal Neoplasms × fludarabine × Clear all

NCT06253520 2026-05-08

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

Phase 1 Active not recruiting

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Ovarian Neoplasms, Urogenital Neoplasms, Colorectal Neoplasms